| Keywords: |
cancer survival; unclassified drug; overall survival; clinical trial; sorafenib; angiogenesis inhibitor; bevacizumab; doxorubicin; erlotinib; placebo; raf protein; sunitinib; advanced cancer; cancer combination chemotherapy; chemoembolization; drug dose reduction; drug efficacy; drug safety; liver cell carcinoma; liver cirrhosis; monotherapy; carcinoma, hepatocellular; clinical trials as topic; drug approval; liver dysfunction; adjuvant therapy; cancer staging; antineoplastic agent; vasculotropin receptor; enzyme inhibition; liver toxicity; combination chemotherapy; platelet derived growth factor receptor; protein serine threonine kinase; imc a 12; protein kinase inhibitors; survival time; drug mechanism; drug response; liver surgery; cancer control; molecular biology; antibiotics, antineoplastic; angiogenesis inhibitors; drug indication; drug choice; insulin like growth factor i receptor inhibitor; pi 88; progen; receptor blocking agent
|
